Thank to your support - Undetectable 14 weeks post Tx

[JackABCD]

Hi Friends,

So happy to tell you.
Just recieved Blood Test 14 weeks post Tx and I am Undetectable.
Also: ALT =  38, AST = 32 , they were around ALT = 230 and AST =  130 before treatement.

Could anyone please tell me what are my chances to remain SVR 6 months post Tx ?

Thank you,
Jack

[Marc1955]

You must be ecstatic! Our friend Jim (jmjm520) is the expert on this – I recall him citing the figure of 95% consistency between three month and six month tests. He basically says you can take this one to the bank. Late re-emergence of the virus occurs more often if you are cirrhotic.

Great news!!

[Marcia2202]

HA! Sound more like 99% to me!!! Congratulations!!! Home free, almost touch down!

[nygirl7]

Yeah I wouldn't be sweating it too much for sure if the virus comes back it's usually in the first month PLUS your liver enzymes are sweeeeet compared to where they used to be (I know that feeling mine were in the mid 200s too!) so I think you have skinned the cat Jack!  :)

Deb agrees with Marcia but adds another few nines 99.999% no WAY those suckers are still around!

[jdwithhcv]

Your chances are great.  Congratulations!

jd

[zazza]

Marvelous news! I am so happy for you! Congratulations!
Za

[apache1]

Congrats !  

Some studies show 3 month eot UND as good as 6 month...

http://aasld2008.abstractcentral.com/planner?NEXT_PAGE=ITINERARY_ABS_DET_POP&SESSION_ABSTRACT_ID=332272&ABSTRACT_ID=504907&SESSION_ID=35383&PROGRAM_ID=2214

AASLD 2008 Annual Meeting
ID#  1253
Nov 03 8:00 AM - 5:30 PM
Q07. HCV: Treatment

Assessment of serum HCV RNA at week 12 post-treatment is as relevant as week 24 to predict SVR in patients with chronic hepatitis C treated with Pegylated interferon plus ribavirin
M. Martinot-Peignoux1; M. Ripault2; S. Maylin1; L. Leclere1; N. Boyer2; P. Marcellin2, 1
1. INSERM U773 -CRB3, HOPITAL BEAUJON, Clichy, 92110, France.
2. Service d'Hépatologie, HOPITAL BEAUJON, Clichy, 92110, France.


Sustained Virologic response (SVR), in patients with chronic hepatitis C treated with pegylated interferon alpha (PEG-IFN) + ribavirin (RBV) is defined by undetectable serum HCV RNA at the end of the 24 weeks post-treatment follow-up period. Once achieved SVR is durable.
The aim of our study was to evaluate if 12 weeks post-treatment serum HCV RNA assessment could be as relevant as 24 weeks to identify patients with SVR.
Methods: 137 patients, consecutively treated with standard of care regimens of PEG-IFN alpha 2b + RBV, with an end of treatment response were included in the study. Serum HCV RNA was measured at 12 weeks and 24 weeks, after treatment cessation. A subset group of patients was analyzed 4 weeks after treatment cessation. SVR was defined as undetectable serum HCV RNA at the end of the 24 weeks post-treatment follow-up. Virologic relapse (VR) was defined as reappearance of detectable HCV RNA during the 24 weeks post-treatment follow-up. Serum HCV RNA was measured with the VERSANTR HCV RNA Qualitative Assay (TMA) (Siemmens). We evaluated the positive predictive value (PPV) of an undetectable serum HCV RNA to identify patients with SVR at week 4 and week 12 post-treatment follow-up.
Results. At the end of the 24 weeks-post treatment follow-up 108/137 (79%) of the patients demonstrated a SVR and 29/137 (21%) patients demonstrated a VR. At week 12 post-treatment follow-up serum HCV RNA was undetectable in 108 patients, all were SVR: PPV for SVR was 100%; 100 patients had normal serum alanine aminotransferase (ALT) level 97 were SVR: PPV for SVR was 97% (CI: 95%-99%). In the patients with VR viral load was: 6.56±0.59 and 6.11± 0.59 log copies/ml (ns) at baseline and at week 12 post-treatment, respectively. At week 4 post-treatment follow-up serum HCV RNA measurements were available for 60 patients (11 VR and 49 SVR), serum HCV RNA was undetectable in 51/60 patients, the PPV for SVR was 96% (CI 93.3%-98.7%).
Conclusions. Our results show that the assessment of serum HCV RNA at week 12 post-treatment follow-up (PPV 100% is as effective as week 24 to predict SVR). This result emphasizes that post-treatment follow-up to identify patients with SVR or VR could be shortened to 12 weeks.

Abstract Central® (patent pending). © ScholarOne, Inc., 2008.

[JackABCD]

Problem with my PC let me return to thank you only after some days.
Thank you all for your great support.
Without this forum I wouldn't go for treatments, especially after my bad experience with treatments before (before Riba).

Just for those who are new here:
I am infected since 1980 from blood transfusion, Geno 1b, Stage 2-3, grade 2-3 before this treatement. I took the treatement for 48 week: Peg + Riba. It was difficult but much less difficult then how it was with the treatement 12 years ago (without Riba, injection every 2 days).

Thank you,
Jack